{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T18:26:36Z","timestamp":1781720796473,"version":"3.54.5"},"reference-count":82,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T00:00:00Z","timestamp":1577923200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Inovio Pharmaceuticals"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.ymthe.2018.10.016","type":"journal-article","created":{"date-parts":[[2018,11,15]],"date-time":"2018-11-15T12:47:01Z","timestamp":1542286021000},"page":"188-199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Development of Novel DNA-Encoded PCSK9 Monoclonal Antibodies as Lipid-Lowering Therapeutics"],"prefix":"10.1016","volume":"27","author":[{"given":"Makan","family":"Khoshnejad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ami","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Wojtak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar B.","family":"Kudchodkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Humeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas N.","family":"Lyssenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Rader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kar","family":"Muthumani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2018.10.016_bib1","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","article-title":"Heart Disease and Stroke Statistics-2017\u00a0Update: A Report From the American Heart Association","volume":"135","author":"Benjamin","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.ymthe.2018.10.016_bib2","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.pop.2012.11.003","article-title":"Hyperlipidemia as a risk factor for cardiovascular disease","volume":"40","author":"Nelson","year":"2013","journal-title":"Prim. Care"},{"key":"10.1016\/j.ymthe.2018.10.016_bib3","doi-asserted-by":"crossref","first-page":"191","DOI":"10.4103\/1947-2714.132916","article-title":"Atherosclerotic cardiovascular disease risk and evidence-based management of cholesterol","volume":"6","author":"Roy","year":"2014","journal-title":"N.\u00a0Am. J. Med. Sci."},{"key":"10.1016\/j.ymthe.2018.10.016_bib4","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cell.2015.01.036","article-title":"A century of cholesterol and coronaries: from plaques to genes to statins","volume":"161","author":"Goldstein","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2018.10.016_bib5","first-page":"99","article-title":"Preventing early cardiovascular death in patients with familial hypercholesterolemia","volume":"114","author":"Repas","year":"2014","journal-title":"J.\u00a0Am. Osteopath. Assoc."},{"key":"10.1016\/j.ymthe.2018.10.016_bib6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1161\/CIRCULATIONAHA.116.022335","article-title":"Long-term risk of atherosclerotic cardiovascular disease in US adults with the familial hypercholesterolemia phenotype","volume":"134","author":"Perak","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.ymthe.2018.10.016_bib7","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrd3699","article-title":"The biology and therapeutic targeting of the proprotein convertases","volume":"11","author":"Seidah","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2018.10.016_bib8","doi-asserted-by":"crossref","first-page":"9820","DOI":"10.1073\/pnas.0903849106","article-title":"A proprotein convertase subtilisin\/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates","volume":"106","author":"Chan","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2018.10.016_bib9","doi-asserted-by":"crossref","first-page":"310","DOI":"10.7150\/ijbs.3524","article-title":"An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes","volume":"8","author":"Zhang","year":"2012","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.ymthe.2018.10.016_bib10","doi-asserted-by":"crossref","first-page":"12882","DOI":"10.1074\/jbc.M110.113035","article-title":"A proprotein convertase subtilisin-like\/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake","volume":"285","author":"Ni","year":"2010","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2018.10.016_bib11","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1194\/jlr.M011445","article-title":"A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in\u00a0vivo","volume":"52","author":"Ni","year":"2011","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.ymthe.2018.10.016_bib12","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1124\/jpet.111.187419","article-title":"Proprotein convertase substilisin\/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates","volume":"340","author":"Liang","year":"2012","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ymthe.2018.10.016_bib13","doi-asserted-by":"crossref","first-page":"11915","DOI":"10.1073\/pnas.0805434105","article-title":"Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates","volume":"105","author":"Frank-Kamenetsky","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2018.10.016_bib14","doi-asserted-by":"crossref","first-page":"e10682","DOI":"10.1371\/journal.pone.0010682","article-title":"A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in\u00a0vitro and in\u00a0vivo","volume":"5","author":"Gupta","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2018.10.016_bib15","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/mt.2011.260","article-title":"PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates","volume":"20","author":"Lindholm","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2018.10.016_bib16","doi-asserted-by":"crossref","first-page":"21992","DOI":"10.1074\/jbc.M111.332643","article-title":"Highly potent inhibitors of proprotein convertase furin as potential drugs for treatment of infectious diseases","volume":"287","author":"Becker","year":"2012","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2018.10.016_bib17","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1002\/cmdc.201500103","article-title":"Novel Furin Inhibitors with Potent Anti-infectious Activity","volume":"10","author":"Hardes","year":"2015","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ymthe.2018.10.016_bib18","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1074\/jbc.272.2.1344","article-title":"Endoprotease activities other than furin and PACE4 with a role in processing of HIV-I gp160 glycoproteins in CHO-K1 cells","volume":"272","author":"Inocencio","year":"1997","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2018.10.016_bib19","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1128\/jvi.69.5.3206-3210.1995","article-title":"Engineered serine protease inhibitor prevents furin-catalyzed activation of the fusion glycoprotein and production of infectious measles virus","volume":"69","author":"Watanabe","year":"1995","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2018.10.016_bib20","doi-asserted-by":"crossref","first-page":"21899","DOI":"10.1074\/jbc.M802444200","article-title":"Inhibition of Chikungunya virus infection in cultured human muscle cells by furin inhibitors: impairment of the maturation of the E2 surface glycoprotein","volume":"283","author":"Ozden","year":"2008","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2018.10.016_bib21","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1021\/jm9012455","article-title":"Potent inhibitors of furin and furin-like proprotein convertases containing decarboxylated P1 arginine mimetics","volume":"53","author":"Becker","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ymthe.2018.10.016_bib22","doi-asserted-by":"crossref","first-page":"e1002468","DOI":"10.1371\/journal.ppat.1002468","article-title":"Human subtilase SKI-1\/S1P is a master regulator of the HCV Lifecycle and a potential host cell target for developing indirect-acting antiviral agents","volume":"8","author":"Olmstead","year":"2012","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ymthe.2018.10.016_bib23","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.antiviral.2014.12.017","article-title":"SKI-1\/S1P inhibitor PF-429242 impairs the onset of HCV infection","volume":"115","author":"Blanchet","year":"2015","journal-title":"Antiviral Res."},{"key":"10.1016\/j.ymthe.2018.10.016_bib24","doi-asserted-by":"crossref","first-page":"e0174483","DOI":"10.1371\/journal.pone.0174483","article-title":"Human Subtilisin Kexin Isozyme-1 (SKI-1)\/Site-1 Protease (S1P) regulates cytoplasmic lipid droplet abundance: A potential target for indirect-acting anti-dengue virus agents","volume":"12","author":"Hyrina","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2018.10.016_bib25","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1593\/neo.08166","article-title":"A small-molecule furin inhibitor inhibits cancer cell motility and invasiveness","volume":"10","author":"Coppola","year":"2008","journal-title":"Neoplasia"},{"key":"10.1016\/j.ymthe.2018.10.016_bib26","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.18632\/oncotarget.2918","article-title":"PACE4 inhibitors and their peptidomimetic analogs block prostate cancer tumor progression through quiescence induction, increased apoptosis and impaired neovascularisation","volume":"6","author":"Levesque","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ymthe.2018.10.016_bib27","doi-asserted-by":"crossref","first-page":"10501","DOI":"10.1021\/jm3011178","article-title":"The Multi-Leu peptide inhibitor discriminates between PACE4 and furin and exhibits antiproliferative effects on prostate cancer cells","volume":"55","author":"Levesque","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ymthe.2018.10.016_bib28","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1593\/neo.92030","article-title":"Proprotein convertase inhibition results in decreased skin cell proliferation, tumorigenesis, and metastasis","volume":"12","author":"Bassi","year":"2010","journal-title":"Neoplasia"},{"key":"10.1016\/j.ymthe.2018.10.016_bib29","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1172\/JCI32040","article-title":"Selective inhibition of proprotein convertases represses the metastatic potential of human colorectal tumor cells","volume":"118","author":"Scamuffa","year":"2008","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2018.10.016_bib30","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1475-2867-14-43","article-title":"Effect of Furin inhibitor on lung adenocarcinoma cell growth and metastasis","volume":"14","author":"Ma","year":"2014","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ymthe.2018.10.016_bib31","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.pep.2008.03.013","article-title":"Recombinant proprotein convertase 4 (PC4) from Leishmania tarentolae expression system: purification, biochemical study and inhibitor design","volume":"60","author":"Basak","year":"2008","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.ymthe.2018.10.016_bib32","doi-asserted-by":"crossref","first-page":"6842","DOI":"10.1073\/pnas.94.13.6842","article-title":"Impaired fertility in mice deficient for the testicular germ-cell protease PC4","volume":"94","author":"Mbikay","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2018.10.016_bib33","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1073\/pnas.0402133101","article-title":"Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype","volume":"101","author":"Maxwell","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2018.10.016_bib34","doi-asserted-by":"crossref","first-page":"48865","DOI":"10.1074\/jbc.M409699200","article-title":"NARC-1\/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol","volume":"279","author":"Benjannet","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2018.10.016_bib35","doi-asserted-by":"crossref","first-page":"50630","DOI":"10.1074\/jbc.M410077200","article-title":"Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin\/kexin type 9a in mouse liver","volume":"279","author":"Park","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2018.10.016_bib36","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1073\/pnas.0335507100","article-title":"The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation","volume":"100","author":"Seidah","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2018.10.016_bib37","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nsmb1235","article-title":"Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia","volume":"14","author":"Cunningham","year":"2007","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ymthe.2018.10.016_bib38","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2018.10.016_bib39","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00439-003-1071-9","article-title":"A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree","volume":"114","author":"Timms","year":"2004","journal-title":"Hum. Genet."},{"key":"10.1016\/j.ymthe.2018.10.016_bib40","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng1509","article-title":"Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9","volume":"37","author":"Cohen","year":"2005","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2018.10.016_bib41","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1086\/500615","article-title":"A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol","volume":"78","author":"Kotowski","year":"2006","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymthe.2018.10.016_bib42","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/clc.22518","article-title":"Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial","volume":"39","author":"Nissen","year":"2016","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.ymthe.2018.10.016_bib43","doi-asserted-by":"crossref","first-page":"526","DOI":"10.7326\/0003-4819-158-7-201304020-00004","article-title":"Discontinuation of statins in routine care settings: a cohort study","volume":"158","author":"Zhang","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ymthe.2018.10.016_bib44","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jama.289.13.1681","article-title":"Statin-associated myopathy","volume":"289","author":"Thompson","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.ymthe.2018.10.016_bib45","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.ymthe.2018.10.016_bib46","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa1105803","article-title":"Effect of a monoclonal antibody to PCSK9 on LDL cholesterol","volume":"366","author":"Stein","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2018.10.016_bib47","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacc.2014.01.006","article-title":"Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials","volume":"63","author":"Raal","year":"2014","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.ymthe.2018.10.016_bib48","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/1471-2261-14-121","article-title":"Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials","volume":"14","author":"Colhoun","year":"2014","journal-title":"BMC Cardiovasc. Disord."},{"key":"10.1016\/j.ymthe.2018.10.016_bib49","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1161\/CIRCULATIONAHA.113.004678","article-title":"Effect of the proprotein convertase subtilisin\/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia","volume":"128","author":"Stein","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.ymthe.2018.10.016_bib50","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ahj.2016.05.010","volume":"178","author":"Ridker","year":"2016","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ymthe.2018.10.016_bib51","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/s41598-017-00316-3","article-title":"Therapeutic efficacy and safety of PCSK9-monoclonal antibodies on familial hypercholesterolemia and statin-intolerant patients: A meta-analysis of 15 randomized controlled trials","volume":"7","author":"Qian","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2018.10.016_bib52","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A Highly Durable RNAi Therapeutic Inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2018.10.016_bib53","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1111\/bcp.12738","article-title":"Antisense-mediated reduction of proprotein convertase subtilisin\/kexin type 9 (PCSK9): a first-in-human randomized, placebo-controlled trial","volume":"80","author":"van Poelgeest","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ymthe.2018.10.016_bib54","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1038\/mtna.2012.16","article-title":"Cholesterol-lowering Action of BNA-based Antisense Oligonucleotides Targeting PCSK9 in Atherogenic Diet-induced Hypercholesterolemic Mice","volume":"1","author":"Yamamoto","year":"2012","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2018.10.016_bib55","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1124\/jpet.114.214221","article-title":"Pharmacologic profile of the Adnectin BMS-962476, a small protein biologic alternative to PCSK9 antibodies for low-density lipoprotein lowering","volume":"350","author":"Mitchell","year":"2014","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ymthe.2018.10.016_bib56","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.atherosclerosis.2008.02.004","article-title":"Berberine decreases PCSK9 expression in HepG2 cells","volume":"201","author":"Cameron","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ymthe.2018.10.016_bib57","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1074\/jbc.M114.597229","article-title":"Inhibition of PCSK9 transcription by berberine involves down-regulation of hepatic HNF1\u03b1 protein expression through the ubiquitin-proteasome degradation pathway","volume":"290","author":"Dong","year":"2015","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2018.10.016_bib58","doi-asserted-by":"crossref","first-page":"28885","DOI":"10.1074\/jbc.M109.052407","article-title":"Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine","volume":"284","author":"Li","year":"2009","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2018.10.016_bib59","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.chembiol.2016.08.016","article-title":"A Small-Molecule Anti-secretagogue of PCSK9 Targets the 80S Ribosome to Inhibit PCSK9 Protein Translation","volume":"23","author":"Petersen","year":"2016","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ymthe.2018.10.016_bib60","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.bbrc.2008.07.106","article-title":"PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide","volume":"375","author":"Shan","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ymthe.2018.10.016_bib61","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.ejmech.2015.01.022","article-title":"LDL-R promoting activity of peptides derived from human PCSK9 catalytic domain (153-421): design, synthesis and biochemical evaluation","volume":"92","author":"Alghamdi","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ymthe.2018.10.016_bib62","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1074\/jbc.M113.514067","article-title":"Identification of a small peptide that inhibits PCSK9 protein binding to the low density lipoprotein receptor","volume":"289","author":"Zhang","year":"2014","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2018.10.016_bib63","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1093\/eurheartj\/ehx260","article-title":"The AT04A vaccine against proprotein convertase subtilisin\/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice","volume":"38","author":"Landlinger","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ymthe.2018.10.016_bib64","doi-asserted-by":"crossref","first-page":"5747","DOI":"10.1016\/j.vaccine.2015.09.044","article-title":"A cholesterol-lowering VLP vaccine that targets PCSK9","volume":"33","author":"Crossey","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2018.10.016_bib65","doi-asserted-by":"crossref","first-page":"e114469","DOI":"10.1371\/journal.pone.0114469","article-title":"Peptide-based anti-PCSK9 vaccines - an approach for long-term LDLc management","volume":"9","author":"Galabova","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2018.10.016_bib66","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2018.10.016_bib67","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10557-016-6685-y","article-title":"Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160\u00a0mg\/dl or Higher","volume":"30","author":"Ginsberg","year":"2016","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.ymthe.2018.10.016_bib68","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.atherosclerosis.2015.11.010","article-title":"Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial","volume":"244","author":"Farnier","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ymthe.2018.10.016_bib69","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","article-title":"Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial","volume":"36","author":"Cannon","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ymthe.2018.10.016_bib70","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1210\/jc.2015-1520","article-title":"Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial","volume":"100","author":"Bays","year":"2015","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ymthe.2018.10.016_bib71","article-title":"PCSK9 Inhibitor Therapies for High Cholesterol: Effectiveness, Value, and Value-Based Price Benchmarks","year":"2015","journal-title":"Draft Report"},{"key":"10.1016\/j.ymthe.2018.10.016_bib72","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1001\/jamacardio.2017.3655","article-title":"Updated cost-effectiveness assessments of PCSK9 inhibitors from the perspectives of the health system and private payers: Insights derived from the FOURIER Trial","volume":"2","author":"Arrieta","year":"2017","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.ymthe.2018.10.016_bib73","doi-asserted-by":"crossref","first-page":"12616","DOI":"10.1038\/srep12616","article-title":"Protection against dengue disease by synthetic nucleic acid antibody prophylaxis\/immunotherapy","volume":"5","author":"Flingai","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2018.10.016_bib74","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41541-017-0020-x","article-title":"DMAb inoculation of synthetic cross reactive antibodies protects against lethal influenza A and B infections","volume":"2","author":"Elliott","year":"2017","journal-title":"npj Vaccines"},{"key":"10.1016\/j.ymthe.2018.10.016_bib75","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/infdis\/jiw111","article-title":"Rapid and Long-Term Immunity Elicited by DNA-Encoded Antibody Prophylaxis and DNA Vaccination Against Chikungunya Virus","volume":"214","author":"Muthumani","year":"2016","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.ymthe.2018.10.016_bib76","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/s41467-017-00576-7","article-title":"An engineered bispecific DNA-encoded IgG antibody protects against Pseudomonas aeruginosa in a pneumonia challenge model","volume":"8","author":"Patel","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2018.10.016_bib77","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00262-017-2042-7","article-title":"Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody","volume":"66","author":"Muthumani","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ymthe.2018.10.016_bib78","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jacl.2017.01.006","article-title":"Statin-associated muscle symptoms-Managing the highly intolerant","volume":"11","author":"Backes","year":"2017","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.ymthe.2018.10.016_bib79","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2217\/clp.12.70","article-title":"Reduction of LDL cholesterol by a monoclonal antibody to PCSK9 in rodents and nonhuman primates","volume":"7","author":"Gusarova","year":"2012","journal-title":"Clin. Lipidol."},{"key":"10.1016\/j.ymthe.2018.10.016_bib80","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/S0140-6736(15)00239-1","article-title":"Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: a randomised, double-blind, placebo-controlled phase 2b trial","volume":"386","author":"Trimble","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2018.10.016_bib81","article-title":"Safety and immunogenicity of an anti\u2013Zika virus DNA vaccine \u2014 preliminary report","author":"Tebas","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2018.10.016_bib82","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ebiom.2018.08.027","article-title":"Synthetic DNA delivery by electroporation promotes robust in\u00a0vivo sulfation of broadly neutralizing anti-HIV immunoadhesin eCD4-Ig","volume":"35","author":"Xu","year":"2018","journal-title":"EBioMedicine"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001618305057?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001618305057?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:55:05Z","timestamp":1761501305000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001618305057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":82,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S1525001618305057"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2018.10.016","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of Novel DNA-Encoded PCSK9 Monoclonal Antibodies as Lipid-Lowering Therapeutics","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2018.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}